Hydrogel compositions and drug delivery systems comprising the same

Patent metadata

Field	Value
Publication number	US-10398647-B2
Application number	US-201715788920-A
Country	US
Kind code	B2
Filing date	Oct 20, 2017
Priority date	Oct 21, 2016
Publication date	Sep 3, 2019
Grant date	Sep 3, 2019

Abstract

A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.

First claim

What is claimed is:

1. A hydrogel composition, comprising:
polyglutamic acid (PGA) containing maleimide groups; and
polyethylene glycol (PEG) containing terminal thiol groups,
wherein the hydrogel composition has a gelation pH value ranging from 4.0 to 6.5.

2. The hydrogel composition as claimed in claim 1 , wherein the polyglutamic acid (PGA) containing maleimide groups has a molecular weight ranging from 10 kDa to 1,000 kDa.

3. The hydrogel composition as claimed in claim 1 , wherein the polyglutamic acid (PGA) containing maleimide groups has a grafting ratio ranging from 5% to 40%.

4. The hydrogel composition as claimed in claim 1 , wherein the polyglutamic acid (PGA) containing maleimide groups has a concentration ranging from 0.75 wt % to 10 wt % in the hydrogel composition.

5. The hydrogel composition as claimed in claim 1 , wherein the polyglutamic acid (PGA) containing maleimide groups is free of thiol groups.

6. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups has a molecular weight ranging from 2 kDa to 20 kDa.

7. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups has a concentration ranging from 0.75 wt % to 10 wt % in the hydrogel composition.

8. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups is 4-arm type, 8-arm type or Y-shape.

9. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups is free of maleimide groups.

10. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups and the polyglutamic acid (PGA) containing maleimide groups have a molar ratio of the thiol group to the maleimide group ranging from 0.2 to 5.0.

11. The hydrogel composition as claimed in claim 1 , wherein the polyethylene glycol (PEG) containing terminal thiol groups and the polyglutamic acid (PGA) containing maleimide groups have a molar ratio of the thiol group to the maleimide group ranging from 1.0 to 1.5.

12. A drug delivery system, comprising:
a hydrogel composition as claimed in claim 1 ; and
a pharmaceutically active ingredient encapsulated in the hydrogel composition.

13. The drug delivery system as claimed in claim 12 , wherein the pharmaceutically active ingredient is selected from the group consisting of growth factors, hormones, peptides, proteins, antibodies, hydrophilic small molecules and hydrophobic small molecules.

14. The drug delivery system as claimed in claim 13 , wherein the pharmaceutically active ingredient is selected from the group consisting of intact antibodies and antibody fragments.

15. The drug delivery system as claimed in claim 13 , wherein the pharmaceutically active ingredient is selected from the group consisting of murine antibodies, chimeric antibodies, humanized antibodies, and human antibodies.

16. The drug delivery system as claimed in claim 13 , wherein the pharmaceutically active ingredient is selected from the group consisting of antineoplastic agents, antipsychotics, analgesics and antibiotics.

17. The drug delivery system as claimed in claim 12 , wherein the pharmaceutically active ingredient is further associated with a polymer, metal, charged compounds or charged particles to form a complex thereof.

18. The drug delivery system as claimed in claim 17 , wherein the polymer comprises polyglutamic acid (PGA), hyaluronic acid, chitosan or dextran.

19. The drug delivery system as claimed in claim 17 , wherein the metal comprises zinc, calcium, magnesium or iron.

20. The drug delivery system as claimed in claim 17 , wherein the complex has a size ranging from 10 nm to 100 μm.

21. The drug delivery system as claimed in claim 17 , wherein the pharmaceutically active ingredient or the complex has a concentration ranging from 1 mg/mL to 300 mg/mL.

Assignees

• Ind Tech Res Inst

Inventors

• Chiang Wen-Hsuan
• Lo Yu-Wen
• Cheng Felice
• Lu Maggie
• Chiu Ya-Ling

Classifications

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title